One team, one vision

At the core, AMYRA consists of a complimentary team of individuals with wide-reaching strengths and competencies. Bound together by trustworthiness and a common vision, each team member is an invaluable part of realising AMYRA’s goal of positively impacting the lives of millions of people around the globe.

Team

Dr. Werner Tschollar

Chief Executive Officer

Werner founded AMYRA Biotech AG. He has over 25 years of experience in the pharmaceutical, biotech and financing industries. He held executive positions in BMS/Princeton, Schering Plough and Novartis, founded several biotech companies and was a co-founder of a large private equity fund in Geneva.

Werner was instrumental for the development and launch of several drugs including, Captopril, Pravastatin, Fosinopril, Taxol, Clopidogrel, Interferon ⍺, Integrelin & Circadin. He has an MD degree and is board certified in clinical pharmacology, holds a degree in Pharmacy and has an MBA.

Dr. Sulay Mourabit

Chief Scientific Officer

Sulay is a dynamic and innovative leader with an extensive background in the life sciences. His research has focused on the molecular biology of inflammation and oxidative stress. He has held senior roles in fundamental and translation research teams, including fields such as Alzheimer’s disease, pediatric neuro-oncology, and ecotoxicology. He has distinguished himself by elevating research programs in academia and industry through multidisciplinary collaborations and forward-thinking approaches. 

At AMYRA Biotech, Sulay oversees the design and execution of the company’s scientific strategy. In his role as CSO, he aims to further the company’s goal of bringing forth effective treatment solutions through groundbreaking research and integrative partnerships.

Marcel Gremaud

Chief Financial Officer

Marcel has 35 years of experience as an auditor, controller, consultant and CFO. He was audit manager at Ernst & Young. Now he is CFO of a publicly traded company on NASDAQ and consultant for international accounting.

Julian Tschollar

Director of Operations

Julian has extensive experience as an independent entrepreneur. During this time, he worked with clients and managers, gathering sales, consultancy and communication expertise. Since joining AMYRA, Julian has been responsible for developing and executing strategic engagement plans and operational activities designed to support key business objectives. 

Mirjam Toews

Director of Finance and Administration

Mirjam has extensive experience in project management, finance, administration and implementation of major events. She is the founder and director of a charitable cultural association. During the COVID-19 pandemic, she co-managed financial support in the cultural sector for the Canton of Basel-Stadt. She holds an Executive Master from the University of Zurich and lives in Basel.

Dr. Peter Stangier

Senior Advisor, Data Sciences

Peter is a results-driven entrepreneur with more than 20 years of experience in the Pharmaceutical and Biotech industry. He has broad knowledge of the Global Pharmaceutical Industry and extensive experience in Strategy & Planning, Market & Competitive Analysis, Forecasting & Financial Valuation, Business Development, and Sales Force Sizing & Effectiveness. In 2013, he founded From Data to Decisions, providing Consulting Services to early stage Life Science Companies.

Lutz Engelhardt

Senior Commercial Advisor

Lutz is an experienced pharmaceutical executive in the OTC field with profound marketing, sales,
and business development expertise. After 25 years of senior management roles in national and
global functions of well-known pharmaceutical companies, he founded the CHC Excellence
consultancy in 2011. Lutz is responsible for developing a competitive product profile, market
positioning and market access strategy.

Dr. Erin Bonner

Senior Scientist

Erin has a rich scientific background in molecular oncology, translational medicine and medical communications.

Her key achievements have been in the field of cancer genomics, clinical management of childhood brain cancers and the development of innovative biomarker assays.

Through Bonner Consulting, Erin provides strategic and scientific advice to companies developing next-generation therapeutics for a range of disease indications.

At AMYRA Biotech, Erin plays a key role in guiding the development of AMYRA’s enzyme technology through preclinical and clinical research and aligning the business strategy with scientific achievements.

Dr. Sven Benson

Senior Biocomputational Enzymologist

Sven has over 10 years of technical and commercial experience in enzyme development for a broad range of industrial and pharmaceutical products, from product inception to launch. He is acting CEO of Candidum GmbH, an enzyme developer with a focus on computational AI technologies.

Joel Mischler

Strategic Fundraising Advisor

Joel, a seasoned independent entrepreneur with nearly a decade of experience, specializes in delivering comprehensive financial and advisory solutions to emerging enterprises. With a remarkable track record, he has successfully orchestrated and procured funding for a diverse array of ventures spanning various industries.

Board of Directors

Dr. Werner Tschollar

Chairman of the Board of Directors

Werner founded AMYRA Biotech AG. He has over 25 years of experience in the pharmaceutical, biotech and financing industries. He held executive positions in BMS/Princeton, Schering Plough and Novartis, founded several biotech companies and was a co-founder of a large private equity fund in Geneva. He has an MD degree and is board certified in clinical pharmacology, holds a degree in Pharmacy and has an MBA.

Dr. Thomas Zehnder

Member of the Board of Directors

Thomas is a co-founder of AMYRA. He has over 20 years of experience in the medtech and healthcare industries as both a senior healthcare executive and an entrepreneur. He holds a MSc from the Swiss Institute of Technology (ETH) in Zurich and a doctorate in Business Administration / Technology Management from the University of St. Gall HSG.

Douglas Gunthardt

Member of the Board of Directors

Douglas has 20 years of international leadership experience with both American high-tech and Swiss life-science corporations, including 8 years as CEO of Siegfried. He is active on boards of Ricola and XiMo, providing expertise on finance and risk management issues.

Dr. Ghassan Azahri

Board Observer

Dr. Ghassan Azhari is the founder and managing partner of Azhari Legal Consultancy in Dubai.  Ghassan founded his firm in 2007 and prior to moving to Dubai, he practiced corporate insolvency and tax law in Berlin.

Ghassan is a specialist in corporate and tax law and advises companies and high net worth clients on structuring their global investments from a legal and tax perspective.

His law firm has a solid experience in the field of the UAE Crypto and Virtual Assets Regulations. Ghassan has an extensive network in the Dubai region and in Asia in the area of financing and among pharmaceutical companies.

Corporate Advisory Board

Dr. Silvio Inderbitzin

Member of the Corporate Advisory Board

Silvio has held senior positions in the pharmaceutical industry during the last 20 years. He held the position of Technical Director/COO/Site manager at Spirig Pharma LTD (Rx/OTC), Switzerland, and ultimately joined the Board of Directors, becoming co-owner of the privately-held 450-employee company. Prior to the successful sale of the company’s various arms, he served as CEO and was responsible for foreign subsidiaries. Meanwhile, Silvio is an active investor, consultant, and board member of several life science start-up companies (listed/private).

Silvio studied pharmacy at the University of Berne, holds a Ph.D. in pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.

André Del Piero

Member of the Corporate Advisory Board

André is a proven expert in Banking and Finance. He has held various senior positions in international financial institutions. André is a Swiss Certified Banking Expert, holds a Master Degree in Corporate Finance CFO and is a Certified Board Member and Certified Foundation Board Member SAQ. He also completed the Executive Program of the Swiss Finance Institute in Zurich. André participated in the Doctoral Program of the University of Gloucerstershire and wrote a research paper on “How Family Offices decide”. Today he advises clients on all financial and strategic topics. His specialties include corporate finance transactions and structuring of capital rounds for corporates.  

Prof. Dr. Benoit Dubuis

Member of the Corporate Advisory Board

Benoît has more than of more than 30 years in the Life Sciences, both in industry and academia. He has held various management positions in pharmaceutical companies (Chemap, Ciba-Geigy/Novartis, Lonza), before joining the the École Polytechnique Fédérale de Lausanne (EPFL), where he founded the Faculty of Life Sciences and was its first dean.

In 2004, he co-founded and became Director of Eclosion, Switzerland’s first incubator and start-up fund in the Life Sciences. Over the years, Benoît has been active with numerous pharmaceutical companies and biotech associations, and founded a number of private and public companies, including Excellgene, GenKyoTex and GeNeuro.

In June 2013, he was appointed Director of the Fondation Campus Biotech Geneva and Director of Development at the Wyss Center.

In 2022, he was appointed President of the of the Swiss Academy of Engineering Sciences to support and accompany Swiss technological development in a global context.

He is also Chairman of the Inartis Foundation, which manages various programs, including Clefs du Savoir, MassChallenge, Espace Création and UniverCité/Station R.

He has published several books and articles on innovation and life sciences.

Scientific Advisory Board

Prof. Dr. Werner Weitschies

Chief Scienfic Advisor

Werner is an expert in pharmaceutical technologies, gastro-intestinal models, formulation development and testing. Since 2003, he he is a Professor of Biopharmaceutics (C4) at the Ernst-Moritz-Arndt-University of Greifswald, Germany. He has published more than 200 peer reviewed articles and 30 patents.

Prof. Dr. Dr. Gerhard Rogler

Member of Advisory Board

Gerhard is a clinical expert for celiac disease. He is scientific advisor to the Swiss Celiac Disease Society. He serves as the Chairman of the Scientific Advisory Board of the University of Zurich and Professor of Gastroenterology and Hematology and Consultant Gastroenterologist at the Zurich University Hospital, Switzerland. He has authored about 200 original peer-reviewed articles.

Prof. Dr. Knut E.A. Lundin

Member of Advisory Board

Knut is Professor of Medicine and Head of Clinical Education at the University of Oslo, Norway. He is also a consultant gastroenterologist at the endoscopy unit at Oslo University Hospital, Rikshospitalet and he is one of the leading European clinicians in the field of celiac disease. Professor Lundin currently serves as the president of the European Society for the Study of Celiac Disease.

Dr. Veronica Dodero

Member of Advisory Board

Veronica currently works at Bielefeld University. Her research spans Organic Chemistry, Chemical Biology and Biophysics. Currently, her principle focus is directed towards understanding the mechanism of peptide/protein self-assembly and its roles in the delicate balance between health and disease in gluten-related disorders. Her research in Functional Molecules, Functional Nanosystems and the role of gliadin has made clear that gluten peptides are not only pathogenic for celiac patients. They possess interesting molecular and supramolecular features that could be used to disclose the mechanism of cellular uptake and be translated into other pathologies like aggregopathies and even cancer. 

Prof. Frits Koning

Member of Advisory Board

Frits is a Professor of Immunology at the Department of Immunohematology and Blood Transfusion at Leiden University. He also serves as Chairman of the Scientific Advisory Board of LUMC (Leiden University Medical Center). Furthermore, he served as the Director of the Celiac Disease Consortium 2004 – 2014.

Prof. Dr. Rolf Bass

Member of Advisory Board

Rolf is an expert for regulatory affairs. He  set up the new Department for European and International Business of the German Federal Institute for Drugs and Medical Devices (BfArM). Today, he is a visiting Professor for Pharmaceutical Medicine, University of Basel, Switzerland where he is responsible for the postgraduate Master curricula for Regulatory Affairs within Pharmaceutical Medicine.

Dr. Gerd Bode

Member of Advisory Board

Gerd is an expert for pre-clinical and clinical drug development. From 2000 to 2005 Gerd Bode was advisor for and lecturer in toxicology at the WHO. Since 2005 he has been a lecturer at several universities and scientific advisory to numerous large and small pharma companies.

Academic Collaborators

Prof. Dr. Werner Weitschies

Chief Scienfic Advisor

Werner is an expert in pharmaceutical technologies, gastro-intestinal models, formulation development and testing. Since 2003, he he is a Professor of Biopharmaceutics (C4) at the Ernst-Moritz-Arndt-University of Greifswald, Germany. He has published more than 200 peer reviewed articles and 30 patents.

Prof. Dr. Mladen Tzvetkov

Mladen is an expert in pharmacogenetics, recombinant DNA technologies, drug transport, and drug analytics. He is a full Professor of Pharmacology and the Head of the Department of General Pharmacology at the University Medicine in Greifswald, Germany. Mladen has co-authored more than 100 peer-reviewed articles.

Prof. Dr. Stefan Engeli

Stefan is an M.D. and board-certified Clinical Pharmacologist with experience in planning and conducting clinical studies since more than 20 years. He is Professor of Clinical Pharmacology at the University Medicine Greifswald since 2021 and Head of the Greifswald Coordinating Center for Clinical Studies (KKS), a core unit of the Medical Faculty. The Institute of Pharmacology is well suited to conduct pharmacokinetic studies.

Sarah Römer

Sarah is a M.Sc. in Human Biology, with a major in Pharmacology. She has been part of the Department of General Pharmacology at the University Medicine Greifswald for 3 years and is working on drug pharmacokinetics and pharmacogenetics. Sarah has a strong background in LC-MS/MS-based drug analytics, drug transport, and genetic analyses.